文献速递脊柱关节炎

美国银屑病关节炎系统治疗模式:2004-2015年

Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-03-23

基于美国大型商业健康计划2004-2015年理赔数据,识别9222例启动DMARD治疗的银屑病关节炎患者,其中42.8%启动生物制剂、57.2%启动传统合成DMARD。随访12个月内20.1%生物制剂启动者与31.1%传统合成DMARD启动者调整方案,方案调整呈上升趋势、完全停药呈下降趋势。

要点

  • 启动生物制剂者较传统合成DMARD启动者更年轻(平均48岁对52岁),合并症一般更少。
  • 甲氨蝶呤占传统合成DMARD启动的80.6%,依那西普(49.1%)与阿达木单抗(34.4%)为最常用生物制剂。
  • 11年间初始DMARD方案调整呈上升趋势(P=0.03),完全停药率随时间下降(P<0.001)。

核心结论

  • 美国银屑病关节炎启动DMARD治疗的患者中超过40%使用生物制剂。
  • 初始DMARD使用后方案调整呈上升趋势,完全停药呈下降趋势。

研究设计与样本

  • 基于美国大型商业健康计划2004-2015年理赔数据的队列研究。
  • 识别9222例启动DMARD治疗的银屑病关节炎患者,分析基线特征与初始治疗模式。
  • 采用泊松回归估计各日历年治疗变化的年龄和性别调整发病率。

主要发现

  • 9222例启动DMARD患者中42.8%为生物制剂、57.2%为传统合成DMARD。
  • 生物制剂启动者平均年龄48±13岁,传统合成DMARD启动者52±14岁,前者合并症一般更少但基线接受银屑病非系统治疗比例更高。
  • 12个月随访中20.1%生物制剂启动者与31.1%传统合成DMARD启动者初始方案被调整。
  • 总体5.3%患者停药。

关键数值与推荐

  • 甲氨蝶呤占传统合成DMARD启动的80.6%。
  • 依那西普占生物制剂处方的49.1%,阿达木单抗占34.4%。
  • 治疗调整随时间呈上升趋势(P=0.03),停药率随时间下降(P<0.001)。

临床怎么用

  • 提示银屑病关节炎临床实践中生物制剂使用比例较高,甲氨蝶呤仍是传统合成DMARD的核心。
  • 治疗过程中方案调整增多、完全停药减少,提示持续优化治疗而非简单停药的模式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine trends in the use of systemic disease-modifying antirheumatic drugs (DMARDs) among patients with psoriatic arthritis (PsA) in the US. METHODS: Using claims data (2004-2015) from a large US commercial health plan, we identified patients with PsA who initiated DMARD therapy. We examined baseline patient characteristics and initial treatment patterns. We then assessed changes in the DMARD regimen over the 12-month period after the first DMARD initiation date. Using Poisson regression, we estimated age- and sex-adjusted incidence rates of treatment changes in each calendar year. RESULTS: We identified 9,222 PsA patients who initiated DMARD therapy (42.8% biologic DMARDs [bDMARDs] and 57.2% conventional synthetic DMARDs [csDMARDs]). Initiators of bDMARDs were younger than those initiating csDMARDs (mean ± SD age 48 ± 13 versus 52 ± 14 years) and generally had fewer comorbidities, but a higher proportion of bDMARD initiators received nonsystemic treatments for psoriasis at baseline. Methotrexate was the most frequently used DMARD, constituting 80.6% of csDMARD initiations. Etanercept (49.1%) was the most commonly prescribed bDMARD, followed by adalimumab (34.4%). During the 12-month followup after the first DMARD initiation, 20.1% of bDMARD initiators and 31.1% of csDMARD initiators had their initial DMARD regimen modified, with an increasing trend in treatment modifications over the 11-year study period (P = 0.03). Overall, 5.3% of patients discontinued treatment, but the rates of discontinuation decreased over time (P < 0.001). CONCLUSION: In this large cohort of PsA patients with DMARD initiation, more than 40% were treated with a bDMARD. We found an increasing trend in treatment modification after use of the initial DMARD and a decreasing trend in complete DMARD discontinuation over the past decade.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Lee MP, Lii J, Jin Y, et al. Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. Arthritis Care Res (Hoboken). 2018. PMID: 28804988. doi:10.1002/acr.23337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。